Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual Meeting Completed enrollment in 80mg PK Run-in Cohort for …